REGENXBIO (NASDAQ:RGNX) Research Coverage Started at Raymond James

Raymond James began coverage on shares of REGENXBIO (NASDAQ:RGNX) in a research report released on Friday. The firm issued an outperform rating and a $27.00 price objective on the biotechnology company’s stock.

RGNX has been the subject of several other reports. Chardan Capital restated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. StockNews.com cut REGENXBIO from a “hold” rating to a “sell” rating in a report on Thursday, January 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.64.

REGENXBIO Stock Down 2.6 %

Shares of RGNX stock opened at $8.21 on Friday. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80. The company has a market cap of $406.72 million, a P/E ratio of -1.63 and a beta of 1.29. The business has a fifty day simple moving average of $8.08 and a 200 day simple moving average of $10.02.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in RGNX. Redmile Group LLC grew its stake in REGENXBIO by 7.1% during the third quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock worth $51,327,000 after purchasing an additional 323,100 shares during the period. Assenagon Asset Management S.A. boosted its holdings in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after acquiring an additional 296,700 shares in the last quarter. Millennium Management LLC boosted its holdings in REGENXBIO by 84.8% in the second quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock worth $3,586,000 after acquiring an additional 140,666 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in REGENXBIO in the fourth quarter worth approximately $1,062,000. Finally, Raymond James Financial Inc. bought a new position in REGENXBIO in the fourth quarter worth approximately $568,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.